Share

    


In This Section

Home / Blurb / Discussion List

Medicare Coverage Established for MRD Testing for ALL, Multiple Myeloma

Jan 23, 2019, 12:27 PM
URL:
On January 17, Adaptive Biotechnologies announced that Palmetto GBA has established coverage of the clonoSEQ Assay for Medicare patients with multiple myeloma and B-cell acute lymphoblastic leukemia (ALL). clonoSEQ is the only test authorized by the U.S. Food and Drug Administration (FDA) to detect and monitor minimal residual disease (MRD) in myeloma and ALL using DNA from a patient’s bone marrow sample. The article is effective immediately and enables national coverage of Medicare patients undergoing testing.

Read the Adaptive Biotechnologies press release here
.

Posted 1/23/2019

Leave a comment